Metabolic Management of Glioblastoma | Thomas Seyfried, PhD

Metabolic Management of Glioblastoma | Thomas Seyfried, PhD

IAOMT Annual Conference in Boston, MA
September 13, 2019

Learning Objectives:
1. Recognize that Glioblastoma, like all cancers, is primarily a mitochondrial metabolic disease, and not a genetic disease.
2. Recognize that Glioblastoma is a disease of defective respiration with compensatory fermentation regardless of the cellular or genetic heterogeneity involved.
3. Recognize that ketogenic metabolic therapy (KMT) is a cost effective, non-toxic therapeutic strategy that targets and kills tumor cells while protecting and enhancing the energy efficiency in normal cells.

Dr. Seyfried is Professor of Biology at Boston College, and received his PhD in Genetics and Biochemistry from the University of Illinois. He also holds a Master's in Genetics from Illinois State University. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine, and then served on the faculty as an Assistant Professor in Neurology. He has received awards and honors from the National Institutes of Health, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, and many other diverse groups. He has over 185 peer-reviewed publications and is author of the book Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).

Disclaimer: The information provided on this video is not intended as medical advice and
should not be interpreted as such. If you seek medical advice, please consult with a health care
professional. Also, the information in this video represents the thoughts of the individual
speaker/s, and the views expressed in this interview do not necessarily reflect the views of the
IAOMT, its individual members, its Executive Committee, its Scientific Advisory Council, its
administration, its employees, contractors, sponsors, or any other IAOMT affiliates.